A naturally occurring nonapeptide first isolated in the 1970s and named for a delta-sleep effect that later research has struggled to confirm.
Reviewed for accuracy · Last reviewed July 8, 2026DSIP (delta sleep-inducing peptide) is a naturally occurring nine-amino-acid peptide first isolated from rabbit brain blood by the Schoenenberger-Monnier group in Basel in the mid-1970s. It was named for an apparent ability to enhance delta-wave (deep) sleep EEG patterns, and early work also linked it to stress, pain, hormonal rhythms, and alcohol and opioid withdrawal.
The evidence is genuinely limited: most human and animal studies are old, small, and inconsistent, and DSIP's role as a true sleep-inducing factor is debated. No DSIP gene, protein, or receptor was ever isolated, and a 2006 review called the sleep hypothesis weak. Treat any claimed benefit as preliminary and unproven. DSIP is not FDA-approved.
There is no standardized or clinically validated human dose for DSIP. Older studies used varied intravenous and subcutaneous amounts, and any figures circulating online are anecdotal rather than based on an approved protocol.
Read the full DSIP dosage guide →The human safety profile is poorly characterized. Older studies described DSIP as generally well tolerated, but the data are thin, old, and not a substitute for modern safety evaluation.
Read the full DSIP side effects guide →As a peptide, DSIP is typically kept lyophilized and refrigerated before mixing, and refrigerated once reconstituted. Handling guidance is generic because no approved label exists. See the full storage & safety guide for handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.